Results 211 to 220 of about 789,890 (303)
Objective Hydroxychloroquine (HCQ) is a cornerstone therapy in systemic lupus erythematosus (SLE), but the weight‐based dosing does not account for clinical factors that can introduce individual variability in drug metabolism and clearance. We leveraged longitudinal data from a prospective SLE cohort to identify clinical factors that predict ...
Jay J. Patel +6 more
wiley +1 more source
From prescribing indicators to rational drug use: a medication safety perspective. [PDF]
Anwar MF, Daud NAA, Hussain R.
europepmc +1 more source
Objective The concern that nonsteroidal anti‐inflammatory drugs (NSAIDs) may precipitate flares of inflammatory bowel disease (IBD) has limited their use in managing musculoskeletal symptoms in those with IBD, but safety data are mixed. Methods This retrospective cohort study included patients with IBD aged at least 18 years from Optum's deidentified ...
Adam S. Mayer +4 more
wiley +1 more source
Development and evaluation of a comprehensive Patient for Medication Safety (PFMS) intervention programme to improve participation in medication safety behaviours among older adults with chronic disease during hospital-to-home transition: a pilot randomized controlled trial. [PDF]
Xu W +5 more
europepmc +1 more source
Clinical, histological, and serological predictors of renal function loss in lupus nephritis.
Objective Kidney survival is the ultimate goal in lupus nephritis (LN) management, but long‐term predictors remain inadequately studied, requiring long‐term follow‐up. This study aimed to identify baseline and early longitudinal predictors of kidney survival in the Accelerating Medicines Partnership LN longitudinal cohort.
Shangzhu Zhang +21 more
wiley +1 more source
Enhancing Continuous Medication Safety Through e-Prescription and Clinical Decision Support Systems in Outpatient Practices and Pharmacies: Protocol for a Multiperspective Study (eRIKA Study). [PDF]
Schmidt J +9 more
europepmc +1 more source
Objective This study aimed to characterize cannabis product choices (cannabinoid content and formulation) among rheumatology patients, and their associations with patient factors, patient reported perceived side effects and positive impacts. Methods An online survey (delivered from March to November 2022) was distributed by Alberta Health Services to ...
Susan Zhang +10 more
wiley +1 more source

